Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.

Bonneterre J, Révillion F, Desauw C, Blot E, Kramar A, Fournier C, Hornez L, Peyrat JP.

Oncol Rep. 2013 Jan;29(1):355-61. doi: 10.3892/or.2012.2090. Epub 2012 Oct 19.

PMID:
23117275
2.

Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.

Zhang K, Yuan K, Wu H, Li Q, Wang Y, Chen S, Zhang L, Gu H, Fu R.

Appl Biochem Biotechnol. 2012 Feb;166(3):753-63. doi: 10.1007/s12010-011-9464-z. Epub 2011 Nov 30.

PMID:
22127810
3.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
4.

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

Oncology. 2011;80(3-4):269-77. doi: 10.1159/000329038. Epub 2011 Jul 7.

PMID:
21734419
5.

[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH.

Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):858-62. Chinese.

PMID:
20137353
6.

Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.

Michishita S, Kim SJ, Shimazu K, Sota Y, Naoi Y, Maruyama N, Kagara N, Shimoda M, Shimomura A, Noguchi S.

Breast. 2015 Apr;24(2):159-65. doi: 10.1016/j.breast.2015.01.001.

PMID:
25805427
7.

Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.

Breast Cancer Res Treat. 2011 Feb;126(1):109-17. doi: 10.1007/s10549-010-1316-y. Epub 2010 Dec 29.

PMID:
21190079
8.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
9.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
10.

Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.

Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, Laurence V, Pierga JY, Fréneaux P, Sigal-Zafrani B, Diéras V, Vincent-Salomon A.

Am J Clin Oncol. 2012 Jun;35(3):242-6. doi: 10.1097/COC.0b013e318209d34c.

PMID:
21358298
11.

Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.

Halim A, Wahba H.

Med Oncol. 2012 Jun;29(2):454-8. doi: 10.1007/s12032-011-9868-1. Epub 2011 Feb 25.

PMID:
21350875
12.

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.

Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C.

Breast Cancer Res Treat. 2011 Nov;130(2):477-87. doi: 10.1007/s10549-011-1715-8. Epub 2011 Aug 12.

PMID:
21837479
13.

[Assessment of neoadjuvant chemotherapy in breast cancer patients].

Zhang B, Zhang Q, Zhao L, Long F, Li S, Jiang DQ, Xu H.

Zhonghua Zhong Liu Za Zhi. 2006 Nov;28(11):867-70. Chinese.

PMID:
17416014
14.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT.

Ann Surg Oncol. 2010 Sep;17(9):2411-8. doi: 10.1245/s10434-010-1008-1. Epub 2010 Apr 6.

15.

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.

Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ.

Eur J Surg Oncol. 2003 May;29(4):361-7.

PMID:
12711290
16.

Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.

Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF.

Am J Clin Oncol. 2015 Feb;38(1):74-9. doi: 10.1097/COC.0b013e31828940c3.

PMID:
23563210
17.

Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.

Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S.

Cancer Invest. 2009 Jun;27(5):521-8. doi: 10.1080/07357900802298096.

PMID:
19479487
18.

Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H.

J Clin Oncol. 2012 Jan 1;30(1):11-8. doi: 10.1200/JCO.2011.35.4639. Epub 2011 Nov 21.

PMID:
22105826
19.

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.

Breast Cancer Res. 2006;8(3):R31. Epub 2006 Jun 21.

20.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.

Sánchez-Rovira P, Seguí MA, Llombart A, Aranda E, Antón A, Sánchez A, Lomas M, Jaén A, Fernández M, Porras I, Dalmau E, Morales S, de la Haba-Rodríguez J.

Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 2013 Feb 9.

Supplemental Content

Support Center